Close

Aldeyra Therapeutics (ALDX) Says First Patient Enrolled in Allergic Conjunctivitis Phase 2b Trial of ADX-102

February 7, 2017 8:10 AM EST Send to a Friend
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login